Crestor: What People Actually Pay for Rosuvastatin in 2026

Rosuvastatin, a statin or HMG-CoA reductase inhibitor marketed as Crestor, has been available in generic form since 2016 in FDA-approved tablets of 5 mg, 10 mg, 20 mg, and 40 mg. While rosuvastatin and atorvastatin (Lipitor) are distinct medications frequently compared to each other, both rank among the most potent statins available in the United States. This review focuses on actual patient costs rather than dosing guidelines or clinical appropriateness, the latter being determinations that belong with the prescribing physician.

Generic rosuvastatin is one of the cheapest chronic medications sold in the United States as of 2026, commonly $4 to $20 for a 30-day supply through discount cards or cash-pay programs, and $0 to $15 as a Tier 1 copay under most commercial and Medicare Part D plans. Brand-name Crestor, when a pharmacy dispenses it instead of the generic, can still cost several hundred dollars a month without a manufacturer coupon. The useful question for most patients is not "does insurance cover this statin" but "am I actually receiving the generic, and is my plan billing it as preventive care."

What is established versus what is reported

This distinction matters more for a cost article than for most clinical topics, because pricing claims come from two very different kinds of evidence:

• Established, checkable facts: FDA approval of generic rosuvastatin in 2016, FDA bioequivalence requirements for generics, USPSTF's statin recommendation for primary prevention, and CMS's general description of Part D generic tiering. These come from regulatory and guideline sources and are the most reliable numbers on this page.
• Reported experience: forum posts, anecdotal pharmacy comparisons, and self-reported satisfaction scores. These describe what happened to specific individuals under specific plans and pharmacies. They are not a substitute for a systematic price survey and they overrepresent people who had either an unusually good or unusually bad experience.

Where the earlier version of this page quoted individual forum posts and cited a specific satisfaction score, those figures could not be verified against a checkable source and have been removed rather than presented as fact. The pricing ranges below reflect commonly reported cash and discount-card prices rather than a single verified national average, and readers comparing prices should confirm current numbers at their own pharmacy, since retail statin pricing shifts by region and by month.

Generic rosuvastatin changed the price picture

AstraZeneca's patent on Crestor expired in 2016, and the FDA approved the first generic rosuvastatin calcium tablets that year, opening the market to multiple manufacturers (FDA Orange Book). Generic competition is the single biggest reason rosuvastatin now costs a fraction of its former brand price. Commonly reported cash and discount-card prices for a 30-day supply of generic rosuvastatin 10 mg or 20 mg fall in the $4 to $20 range at major U.S. retail pharmacies, and some cash-pay programs advertise 90-day supplies for roughly $10 to $25.

Brand-name Crestor is still manufactured and occasionally dispensed. Without a manufacturer copay card, a 30-day supply of brand Crestor is widely reported to run into the hundreds of dollars, far above the generic price. Patients who are dispensed brand instead of generic, whether by pharmacy error, formulary quirk, or a "dispense as written" instruction on the prescription, are the ones most likely to describe a large, unexpected bill.

The FDA requires a generic drug to demonstrate bioequivalence, meaning it delivers the same active ingredient into the bloodstream at a comparable rate and extent as the brand product, before it can be approved, according to FDA regulatory standards for generic drug approval. This is the regulatory basis for treating brand and generic rosuvastatin as clinically interchangeable; it is not, by itself, a statement about any individual patient's response.

What insured patients report paying

Generic rosuvastatin is typically placed on Tier 1, the lowest cost-sharing tier, by commercial pharmacy benefit managers, which is consistent with copays of $0 to $15 per month reported across insured patients. Some ACA-compliant plans cover statins with no cost-sharing at all when the prescription is written for primary cardiovascular prevention in a patient who meets USPSTF criteria, under the ACA's preventive-services cost-sharing rule.

The USPSTF recommends statin use for adults aged 40 to 75 who have at least one cardiovascular risk factor and an estimated 10-year cardiovascular risk of 10% or greater (USPSTF recommendation, accessed 2026). When a prescription is coded against this recommendation, the plan is generally required to cover it without a copay; when it is coded as a general prescription rather than preventive care, standard cost-sharing can apply even for the same drug and the same patient. Whether a particular fill gets the preventive code often depends on how the prescriber and pharmacy submit the claim, which is why two patients on similar plans can report different copays for the same medication.

Medicare Part D plans generally place generic rosuvastatin on a low generic tier as well, and CMS's general description of Part D generic drug coverage reflects that lower tiers carry lower cost-sharing (CMS.gov, accessed 2026). Exact copay amounts vary by plan and by year, so a specific dollar figure for a specific Part D plan should be confirmed on that plan's current formulary rather than assumed from a general description.

A framework for reading rosuvastatin cost claims

Cost claims about any drug tend to arrive in three different evidentiary tiers, and mixing them together is where most misleading "what people pay" content comes from. Use this table to sort a claim before acting on it.

The practical decision rule that follows: if a specific number in a cost article cannot be traced to the top two rows of this table, treat it as anecdote, verify it against your own plan or pharmacy before relying on it, and do not assume it generalizes.

What uninsured and cash-pay patients report

Rosuvastatin frequently appears on major retail pharmacy discount generic programs and on price-comparison platforms alongside other generic statins, with reported 30-day cash prices commonly in the single digits to roughly $20 depending on pharmacy and location. Cash-pay pharmacy models that publish a transparent per-unit markup have advertised 90-day supplies of rosuvastatin 20 mg priced near or below the cost of a coffee subscription, though exact current pricing should be checked directly on the pharmacy's own site since these prices are updated and can change.

The gap between these real-world prices and the Average Wholesale Price (AWP) listed in pharmacy pricing databases is large; AWP is a benchmark used for billing and reimbursement calculations, not a price most cash-pay patients actually encounter at the register.

Brand-name Crestor: who still pays a premium

A small share of rosuvastatin prescriptions are still filled as brand Crestor rather than generic. This tends to happen for a few specific reasons: a prescriber writes "dispense as written," a patient uses a manufacturer copay card that makes brand and generic similarly priced out of pocket while the insurer absorbs the difference, or a particular pharmacy or plan design does not default to generic substitution. Patients who encounter a several-hundred-dollar bill for rosuvastatin are almost always looking at a brand-dispensed fill rather than the generic, and asking the pharmacist to substitute the generic, or confirming with the prescriber that generic substitution is permitted, is the direct fix.

How rosuvastatin costs compare to other statins

At the generic level, rosuvastatin is priced similarly to atorvastatin, simvastatin, and pravastatin, generally in the low single digits to roughly $20 for a 30-day supply depending on pharmacy and discount program. Atorvastatin became generic in 2011, five years before rosuvastatin, and remains more commonly prescribed in the U.S. than rosuvastatin overall; this gap is plausibly influenced by prescribing habits formed before rosuvastatin had a generic, though the precise magnitude of that effect would need to be checked against current prescribing data rather than assumed. From a pure cost standpoint, there is little financial reason to prefer one high-intensity statin over the other once both are generic.

Reported satisfaction and its limits

Online reviews and forum threads about rosuvastatin commonly describe muscle aches and fatigue as the most frequent complaints, and describe cost satisfaction as generally high once a patient is confirmed to be on the generic. These patterns are directionally consistent with what is known about statins as a drug class, but a specific average satisfaction score cannot be reliably sourced for this page and has been left out rather than stated as fact.

Forum-based cost and satisfaction reports also carry a selection bias worth naming directly: patients who hit a billing surprise or a side effect are more likely to post about it than patients whose prescription was filled routinely and without incident. A large share of the millions of Americans taking a statin never post about their experience at all (CDC statin use data brief), so forum threads tend to overrepresent both unusually good and unusually bad experiences relative to the typical one.

Strategies that consistently lower out-of-pocket cost

A few approaches show up repeatedly across pricing benchmarks and plan-design literature:

1. Ask the pharmacist or prescriber to confirm the prescription is for generic rosuvastatin, not brand Crestor, especially if a "dispense as written" instruction may be on file.
2. Compare cash and discount-card prices across two or three pharmacies before filling; generic statin prices vary meaningfully by pharmacy even within the same zip code.
3. Ask about a 90-day fill, which is often cheaper per tablet than three separate 30-day fills.
4. Confirm whether your prescription is billed under a preventive-care code if you meet USPSTF criteria for primary prevention; this determines whether ACA no-cost-sharing rules apply.
5. If uninsured, check current cash-pay pharmacy pricing directly, since advertised list prices for generic statins change and should be verified at the time of filling rather than assumed from an older figure.

Adherence to lipid-lowering therapy is itself a cost-relevant variable: patients who cannot sustain a regimen because of cost or side effects do not get the drug's benefit regardless of price. A 2026 analysis of prevention strategies for sustainable lipid-lowering management underscores that keeping patients consistently on therapy, not just getting them a first low-cost fill, is central to realizing statins' preventive benefit (BRING-UP prevention study, 2026); the specific strategies and population in that study should be checked directly before citing its findings as generalizable to a particular patient group.

When higher doses affect price

Generic rosuvastatin's 5 mg, 10 mg, 20 mg, and 40 mg strengths are commonly priced within a few dollars of each other for a 30-day supply, so pill-splitting offers little savings compared with some other medications. The 40 mg dose, the maximum FDA-approved strength, occasionally requires prior authorization on some formularies, with plans preferring a trial of 20 mg first. Current cholesterol management guidelines support high-intensity statin therapy, which includes rosuvastatin at 20 to 40 mg, for patients with established atherosclerotic cardiovascular disease or very high LDL cholesterol; the specific dose and whether high-intensity therapy is appropriate for a given patient is a decision for the prescribing clinician, not something this page can determine.

The cost of untreated risk, stated cautiously

Statin therapy is broadly supported by large trial evidence as reducing cardiovascular events in appropriate patients, and untreated cardiovascular disease carries substantial downstream medical costs, including hospitalization for a first heart attack or stroke. Precise effect sizes for specific trials (such as relative risk reductions, numbers needed to treat, or cost-per-QALY estimates) are widely cited in the cardiology literature, but this page does not carry a verified citation for those exact figures and readers should check the primary trial publications or a current AHA/ACC or USPSTF summary before relying on a specific number. What can be stated plainly is the direction of the evidence: for patients who meet guideline criteria for statin therapy, the monthly cost of generic rosuvastatin is low relative to the medication's demonstrated role in reducing cardiovascular risk, and cost is rarely a good reason to avoid or discontinue therapy in an eligible patient without first checking generic pricing, discount programs, and preventive-care billing options.

When to seek care rather than troubleshoot cost

Cost questions are separate from safety questions. Unexplained muscle pain, dark urine, unusual weakness, or signs of an allergic reaction after starting rosuvastatin warrant contacting a prescriber promptly rather than simply switching pharmacies to save money, and severe symptoms warrant urgent evaluation. Stopping a prescribed statin because of cost confusion, without discussing it with the prescriber, is not a substitute for resolving the billing issue.